Showing papers by "Daniel Rachmilewitz published in 2009"

TL;DR: The ACT-1 and ACT-2 randomized, double-blind, placebo-controlled studies evaluated infliximab induction and maintenance therapy in moderately to severely active ulcerative colitis as mentioned in this paper.

TL;DR: Patients with moderately to severely active ulcerative colitis treated with infliximab were less likely to undergo colectomy through 54 weeks than those receiving placebo.